Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Revenue data on file, last reported at $7.6 million in Q1 2026.

• Revenue for Q1 2026 came in at $7.6 million, down 90.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 348.16% YoY), and the FY2025 annual result was $1.3 billion, up 339.54% from the prior year.
• Revenue declined to $7.6 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Revenue peaked at $1.0 billion in Q4 2025 and troughed at -$172.3 million in Q4 2022.
• A 5-year average of $153.1 million and a median of $70.9 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue slumped 141.4% in 2024, then jumped 2516.76% in 2025.
• A 5-year view of Revenue shows it stood at -$172.3 million in 2022, then jumped by 439.52% to $585.1 million in 2023, then slumped by 93.15% to $40.1 million in 2024, then jumped by 2516.76% to $1.0 billion in 2025, then slumped by 99.28% to $7.6 million in 2026.
• Business Quant data shows LKFT's Revenue at $7.6 million in Q1 2026, $1.0 billion in Q4 2025, and $83.2 million in Q3 2025.